ALASKA MEDICAID
Prior Authorization Criteria

# Oxbryta™ (voxelotor)

## FDA INDICATIONS AND USAGE[1]

Oxbryta™ is indicated to treat sickle cell disease in patients 12 years of age and older. It is a hemoglobin S polymerization inhibitor that was approve under the accelerated pathway. The drug is thought to inhibit red blood cell sickling, improve red blood cell deformity, and reduce whole blood viscosity.

## APPROVAL CRITERIA[1,2]

1. Patient is 12 years of age or older AND;
2. Patient has the diagnosis of sickle cell disease AND;
3. Prescribed by or consultation with a hematologist or a provider that specializes in sickle cell disease AND;
4. Documentation that the patient has had at least one vaso-occlusive crisis within the past 6 months AND;
5. Has a documented baseline hemoglobin AND;
6. Patient has tried and failed or has a contraindication to hydroxyurea for at least 3 months.

## DENIAL CRITERIA[1,2]

1. Failure to meet approval criteria OR;
2. Patient is receiving concomitant, prophylactic blood transfusions OR;
3. Concomitantly being prescribed with Adakveo.

## CAUTIONS[1]

- Concomitant use of moderate to strong CYP3A4 inhibitors should be avoided.
- Monitor for hypersensitivity reactions and manage promptly.

## DURATION OF APPROVAL

- Approval: Up to 3 months
- Reauthorization: Up to 12 months with documentation showing an increase in hemoglobin and/or decrease in vaso-occlusive crisis related emergencies.

## QUANTITY LIMITS

- 90 – 500mg tablets per 30 days

**REFERENCES / FOOTNOTES:**

1. Oxbryta™ [prescribing information]. San Francisco, CA: Global Blood Therapeutics; November 2019.
2. Brown C, Hoppe C, Inati A, et al. Efficacy and Safety of 1500 mg Voxelotor in a Phase 2a Study (GBT440-007) in Adolescents with Sickle Cell Disease. Blood:132(Suppl 1):509. Accessed November 26, 2019.